We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$7.48B
1-Year Est. Return
104.76%
This Fund
S&P 500
This Quarter
Est. Return
+37.69%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.48B
AUM Growth
+$1.44B
(+24%)
Cap. Flow
-$77.6M
Cap. Flow
% of AUM
-1.04%
Top 10 Holdings %
Top 10 Hldgs %
23.83%
Holding
336
New
58
Increased
161
Reduced
69
Closed
35
Avg Time Held
6.6
quarters
Top 10 Avg Time Held
4.2
quarters
Top 20 Avg Time Held
4.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalyn Pharma
AVLN
|
+$39.7M |
| 2 |
Cadence Design Systems
CDNS
|
+$29.6M |
| 3 |
Remitly
RELY
|
+$27.3M |
| 4 |
Dell
DELL
|
+$25.5M |
| 5 |
Fifth Third Bancorp
FITB
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xometry
XMTR
|
+$57.8M |
| 2 |
Prologis
PLD
|
+$56.1M |
| 3 |
Guardant Health
GH
|
+$44M |
| 4 |
Axsome Therapeutics
AXSM
|
+$44M |
| 5 |
Global E Online
GLBE
|
+$37.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.37% |
| 2 | Technology | 22.57% |
| 3 | Industrials | 20.48% |
| 4 | Energy | 5.51% |
| 5 | Utilities | 4.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Willis Towers Watson
WTW
$27.7B
| $15.9M | 0.21% |
60,725
-2,388
| -4% | -$639K |
2026 Q1
1 quarter
|
|
127
NXP Semiconductors
NXPI
$56.8B
| $15.8M | 0.21% |
+56,232
| New | +$15.5M |
2026 Q2
0 quarters
|
|
128
Advanced Micro Devices
AMD
$973B
| $15M | 0.2% |
26,328
+9,802
| +59% | +$4.02M |
2024 Q4
6 quarters
|
|
129
Diamondback Energy
FANG
$55.6B
| $15M | 0.2% |
84,257
+16,348
| +24% | +$3.17M |
2023 Q2
12 quarters
|
|
130
Home Depot
HD
$292B
| $14.9M | 0.2% |
42,396
+8,209
| +24% | +$2.67M |
2024 Q2
8 quarters
|
|
131
United Therapeutics
UTHR
$23.5B
| $14.7M | 0.2% |
27,101
-1,451
| -5% | -$817K |
2024 Q2
8 quarters
|
|
132
Achieve Life Sciences
ACHV
$721M
| $14.5M | 0.19% |
+2,220,000
| New | +$10.6M |
2026 Q2
0 quarters
|
|
133
Ciena
CIEN
$56.2B
| $14.5M | 0.19% |
29,559
+25,548
| +637% | +$13M |
2024 Q3
7 quarters
|
|
134
Caterpillar
CAT
$350B
| $13.8M | 0.18% |
13,306
+1,507
| +13% | +$1.32M |
2025 Q3
3 quarters
|
|
135
Amgen
AMGN
$222B
| $13.8M | 0.18% |
38,166
+9,519
| +33% | +$3.26M |
2024 Q1
9 quarters
|
|
136
Kailera Therapeutics
KLRA
$1.41B
| $13.6M | 0.18% |
+616,720
| New | +$13.6M |
2026 Q2
0 quarters
|
|
137
Pentair
PNR
$8.44B
| $13.6M | 0.18% |
177,107
-82,488
| -32% | -$6.53M |
2020 Q4
22 quarters
|
|
138
Xylem
XYL
$23.9B
| $13.5M | 0.18% |
113,944
+509
| +0.4% | +$58.8K |
2025 Q1
5 quarters
|
|
139
Praxis Precision Medicines
PRAX
$6.79B
| $13M | 0.17% |
38,684
+44
| +0.1% | +$13.9K |
2025 Q4
2 quarters
|
|
140
Relmada Therapeutics
RLMD
$363M
| $12.9M | 0.17% |
1,858,416
+1,016,310
| +121% | +$7.1M |
2026 Q1
1 quarter
|
|
141
Halliburton
HAL
$27.3B
| $12.8M | 0.17% |
375,474
-193,072
| -34% | -$7.54M |
2025 Q4
2 quarters
|
|
142
Lithia Motors
LAD
$6.27B
| $12.7M | 0.17% |
43,813
+1,245
| +3% | +$354K |
2023 Q1
13 quarters
|
|
143
Lumentum
LITE
$88B
| $12.6M | 0.17% |
14,672
-199
| -1% | -$178K |
2025 Q2
4 quarters
|
|
144
Tango Therapeutics
TNGX
$3.72B
| $12.5M | 0.17% |
+400,000
| New | +$9.89M |
2026 Q2
0 quarters
|
|
145
Linde
LIN
$227B
| $11.6M | 0.16% |
22,433
+1,781
| +9% | +$902K |
2023 Q3
11 quarters
|
|
146
ServiceTitan Inc
TTAN
$6.97B
| $11.5M | 0.15% |
162,882
+61
| +0% | +$3.93K |
2025 Q3
3 quarters
|
|
147
ExxonMobil
XOM
$717B
| $11.3M | 0.15% |
83,010
+19,516
| +31% | +$2.92M |
2025 Q1
5 quarters
|
|
148
Medtronic
MDT
$118B
| $11.1M | 0.15% |
138,227
+24,493
| +22% | +$1.98M |
2025 Q2
4 quarters
|
|
149
Group 1 Automotive
GPI
$2.72B
| $11M | 0.15% |
37,770
-5,067
| -12% | -$1.66M |
2023 Q3
11 quarters
|
|
150
International Paper
IP
$16.7B
| $10.8M | 0.15% |
284,624
-360,814
| -56% | -$12.4M |
2024 Q2
8 quarters
|
|
Similar funds
S
CCM
O
HI
HPC
FPP
RIG
TAM
Eventide Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Eventide Asset Management held 336 positions worth $7.48B, up 24% from $6.05B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Eventide Asset Management's Q2 2026 filing shows 58 new, 161 increased, 69 reduced and 35 closed positions. Its largest new stake was Avalyn Pharma: 1,375,486 shares worth $45.3M. The largest sale was Xometry, an estimated $57.8M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q2 2026 buy was Avalyn Pharma: 1,375,486 shares worth $45.3M.
- Eventide Asset Management added most to Cadence Design Systems in Q2 2026, an estimated $29.6M increase.
- Eventide Asset Management's biggest Q2 2026 reduction was Xometry, cutting an estimated $57.8M.
- Eventide Asset Management fully exited Prologis in Q2 2026, selling an estimated $56.1M.
- Eventide Asset Management's ten largest holdings make up 24% of its $7.48B portfolio in Q2 2026.
- Eventide Asset Management opened 58 new positions and closed 35 in Q2 2026.
- Eventide Asset Management's portfolio value rose 24% quarter-over-quarter to $7.48B.
Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.